Scope of the Study
Bulimia is an eating disorder which allows people to binge eat. Then, the individual takes steps for weight loss which includes excessive exercising. The treatment of bulimia nervosa includes counseling, medication and nutrition education. This disease can last a year or lifelong. It is elf diagnosed and treated by medical professionals. However, the lab tests are rarely required. Moreover, the treatment includes various therapies and drugs such as antipsychotic and others.
The market study is being classified and major geographies with country level break-up.
Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Forest Pharmaceuticals, Inc. (United States), Pfizer, Inc. (United States), Bristol-Myers Squibb (United States), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Allergan, Inc. (Ireland), Dr. Reddy’s Laboratories Limited (India) and Lupin Pharmaceuticals, Inc. (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bulimia Nervosa Treatment market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Bulimia Nervosa Treatment market by Type, Application and Region.
On the basis of geography, the market of Bulimia Nervosa Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Prevalence of Cardiovascular Diseases is leading to Bulimia Nervosa
- Increasing Intake of Alcohol Is Leading to This Disease which is fueling the Market Growth
- Decreasing Effect of these Disease in Younger Generation due to the Adoption of Healthy Eating
- High Costs Associated with the Treatment
- Lack of Specific Drugs for the Treatment of Bulimia Nervosa
- Developments of Healthcare Infrastructure
- Government Initiatives towards Healthcare
- Lack of Awareness among the People
Market Leaders and their expansionary development strategies
On 17th June 2019, Pfizer has acquired Array biopharma which is focused on development and commercialization of small molecule drugs.
Key Target AudienceDrug Manufacturers, Raw material suppliers, Government associations, Research organizations, Enterprise software vendors and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase